Nobody dares stopping clinical research, not even COVID-19
In the global health emergency caused by the COVID-19, clinical trial management has proven to be critical for the pharmaceutical industry, sponsors, and healthcare professionals. Our experience as a sponsor managing interventional oncology clinical studies has provided us with some data and insight...
Guardado en:
Autores principales: | Andrea Malfettone, Serena Di Cosimo, José Manuel Pérez-García, Alicia García, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortés |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/33b48eb9a9dd438c9f6dd121fdf66906 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: María Gion, et al.
Publicado: (2021) -
“Nobody Seems to Know Where to Even Turn To”: Barriers in Accessing and Utilising Dementia Care Services in England and The Netherlands
por: Clarissa Giebel, et al.
Publicado: (2021) -
Nobody Is Forgotten, Nothing Is Forgotten!
por: Valery P. Gridnev
Publicado: (2021) -
Telling stories that nobody wants to hear
por: Susan Eisenhuth
Publicado: (2010) -
THE SITUATION OF THE STRANGER IN LIQUID MODERNITY: THE PROCESS OF BECOMING NOBODY
por: Doğa BAŞER, et al.
Publicado: (2019)